Volume 26, Issue 7, July 2021

This commentary is a call to action: that all patients with cancer and their families should receive care that aligns with their values and unique priorities. This is the vision of the Improving Goal Concordant Care (IGCC) Initiative, convened by the Alliance of Dedicated Cancer Centers (ADCC).

Traditionally, Black men with prostate cancer have had higher incidence and lower rates of survival. This article addresses barriers in screening, diagnosis, treatment, and community education that contribute to the disparate burden of prostate cancer among multiple populations and highlights innovative ways that new developments and advances can be more broadly disseminated and used for all patients with prostate cancer.

This case report highlights the role of immunotherapy after administration of alkylating agents, reporting the first known case of a patient with myxofibrosarcoma who developed high tumor mutational burden after temozolomide monotherapy.

This article reports the case of an adult patient diagnosed with giant unresectable mesenteric cystic lymphangioma, highlighting the importance of molecular characterization of these rare tumors for mTOR pathway activation and the multidisciplinary therapeutic options that can lead to cure of this rare condition.

Describing a cohort of patients with HR+/HER2− advanced breast cancer treated with abemaciclib, this article evaluates the prognostic association between pretreatment patient-reported outcomes and progression-free survival, the prediction performance of patient-reported outcomes compared with ECOG performance status, and the effect of patient-reported outcomes on the treatment benefit of abemaciclib versus comparator therapy.

This article reports the efficacy of treatment with alpelisib combined with fulvestrant in a cohort of patients with PIK3CA-mutated breast cancer compared with the effectiveness of real-world standard treatments in the post-CDK4/6i setting using data from a deidentified clinico-genomics database (CGDB).

The most frequently reported treatment-related adverse event in clinical trials with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib is neutropenia. In this study, pharmacogenetic analyses were performed to uncover associations between single nucleotide polymorphisms in the ABCB1 and ERCC1 genes, patient baseline characteristics, and early occurrence of grade 3/4 neutropenia.

This article assesses the effects of COVID-19 on the number of newly diagnosed breast cancer patients in the Republic of Croatia.

This article characterizes the ctDNA genomic alteration landscape in patients with advanced pancreatic ductal adenocarcinoma, with a focus on actionable findings.

The clinical significance of HER2 somatic mutations and its relationship with high microsatellite instability in colorectal cancer is not fully understood. This study investigated the relationship by analyzing data of patients with colorectal cancer who underwent next-generation sequencing.

This review explores key challenges with depot-based treatment of gastroenteropancreatic neuroendocrine tumors with octreotide and the key differences between the LAR and IR formulations.

The phase III PROSELICA and FIRSTANA trials investigated taxane chemotherapy among men with post-docetaxel metastatic castration-resistant prostate cancer (mCRPC) or chemotherapy-naïve mCRPC, respectively. This article analyzes patient-reported health-related quality of life among patients with or without a clinical (pain, tumor, or prostate-specific antigen) response.

Oncology providers in low- and middle-income countries face resource priority setting decisions on a routine basis. This article describes the moral experience and recommendations of oncology clinicians, advisors, and program leaders engaged in clinical priority setting at a cancer center in Rwanda.

Guidelines to improve and standardize oncology care in Tanzania were developed in 2020. This study utilized focus group discussions to assess the barriers and facilitators to guideline implementation at Ocean Road Cancer Institute.

There is a paucity of data in the literature characterizing the patterns of care as pertains to race within the various disease subsites in head and neck cancer. This article examines the differences in adherence to guideline-concordant care and associations with the racial disparity in the survival of nonmetastatic cases of head and neck squamous cell carcinoma overall and across tumor sites and stages.

This article assesses the economic burden exhibited by patients with cancer enrolled in early-phase clinical trials by examining out-of-pocket medical and nonmedical costs and patient-reported financial toxicity.

This article reports on the association between immune-related adverse events and health care resource utilization, costs, and mortality among patients receiving PD-1/PD-L1 immune checkpoint inhibitor monotherapy for urothelial carcinoma, renal cell carcinoma, non-small cell lung cancer, or Merkel cell carcinoma.

This article presents data on a large number of patients with primary mediastinal (thymic) large B-cell lymphoma and reports a powerful prognostic factor analysis to identify high- or low-risk risk subgroups for risk-adapted therapy.

This article focuses on the therapeutic potential of immune-checkpoint inhibitors for advanced hepatocellular carcinoma.

Racial disparities in clinical trials affect whether trial results can be generalized for diverse patient populations. This article evaluates real-world data to assess the impact of race and ethnicity on treatment response in patients with advanced non-small cell lung cancer treated with PD-1 or PD-L1 inhibitors.

This article reports the results of a prospective clinical trial of vismodegib for patients with basal cell carcinoma occurring in the orbital and periocular regions to assess whether such treatment helps to preserve visual organs and function.

This article summarizes the regulatory review of data leading to the approval of borofalan in Japan.

This article reports the results of a phase Ib/II trial to evaluate the safety and efficacy of anlotinib, vincristine, and irinotecan in patients with advanced Ewing sarcoma.

Histiocytic and dendritic cell neoplasms are a diverse group of tumors arising from the monocytic or dendritic cell lineage. This article presents the molecular characteristics of the four major subtypes of malignant histiocytic and dendritic cell neoplasms, focusing on genomic alterations that could represent therapeutic targets.

Hand-foot skin reaction is a common regorafenib-induced adverse event. This article reports on the use of topical clobetasol and its role when administered preventively, before a skin reaction occurs.

XPO1 inhibitors are associated with distinct adverse events. This article focuses on ocular adverse events in patients with advanced malignancies treated with selinexor.

Disparities exist in the quality of end-of-life care. This article assesses the quality of care for dying cancer patients, as perceived by bereaved relatives, within hospitals in seven European and South American countries.

This letter to the editor highlights additional analyses to add to the recently reported study by Rugo et al., regarding abemaciclib treatment for HR+/HER2− breast cancer.

This letter to the editor responds to Badoui et al. regarding data on abemaciclib dosages and adverse events.

Adding to the limited literature on the subject, this letter to the editor focuses on the trend in the use of stereotactic radiation therapy for metastatic renal cell carcinoma.